Cuprina to acquire Singapore clinics for S$4.0 million
Singapore-based biomedical firm Cuprina Holdings has entered into agreements to acquire two clinics in Singapore for approximately S$4.0 million. The deal, finalized by Cuprina Holdings (BVI) Limited, will be paid 75% in cash and 25% in the company's shares. The cash portion of S$3.0 million is payable upfront, with the remainder spread across two installments.
Shares, subject to a lock-up period, will also be exchanged. Cuprina Holdings will assume the combined revenue of S$9.1 million and normalized EBITDA of S$1.2 million for the year ending December 31, 2025. The transaction, expected to close by November 1, 2026, hinges on customary closing conditions. Post-acquisition, financial results will be consolidated under Cuprina's umbrella.
Cuprina specializes in developing products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
